The Goldman Sachs Group, Inc. 13D and 13G filings for Larimar Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-13 11:33 am Sale | 2025-03-31 | 13G | Larimar Therapeutics, Inc. LRMR | GOLDMAN SACHS GROUP INC GS | 2,600,211 4.100% | -1,891,806 (-42.11%) | Filing |
| 2024-11-06 2:29 pm Purchase | 2024-09-30 | 13G | Larimar Therapeutics, Inc. LRMR | GOLDMAN SACHS GROUP INC GS | 4,492,017 7.000% | 4,492,017 (New Position) | Filing |